title: Idiosyncratic liver injury induced by vildagliptin with successful switch to linagliptin in a hemodialyzed diabetic patient.
authors.affiliation: Center for Innovative Research for Communities and Clinical Excellence, Fukushima Medical University, Fukushima, Japan Department of Medicine, Mikamikai Yasu Hospital, Shiga, Japan Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan kurita_n@opal.plala.or.jp.
authors.forename: Noriaki
authors.initials: N
authors.lastname: Kurita
authors.affiliation: Department of Nursing, Mikamikai Yasu Hospital, Shiga, Japan.
authors.forename: Takako
authors.initials: T
authors.lastname: Ito
authors.affiliation: Department of Medicine, Mikamikai Yasu Hospital, Shiga, Japan Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan.
authors.forename: Sayaka
authors.initials: S
authors.lastname: Shimizu
authors.affiliation: Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan Foundation for Biomedical Research and Innovation, Hyogo, Japan.
authors.forename: Takumi
authors.initials: T
authors.lastname: Hirata
authors.affiliation: Department of Medicine, Mikamikai Yasu Hospital, Shiga, Japan.
authors.forename: Hirotsugu
authors.initials: H
authors.lastname: Uchihara
mesh_terms: D000218:Adamantane / Q000009:adverse effects / Q000031:analogs & derivatives*; D000368:Aged; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D003920:Diabetes Mellitus / Q000503:physiopathology*; D003928:Diabetic Nephropathies / Q000150:complications* / Q000628:therapy; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000069476:Linagliptin; D009570:Nitriles / Q000009:adverse effects*; D011687:Purines / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000009:adverse effects*; D011799:Quinazolines / Q000627:therapeutic use*; D006435:Renal Dialysis; D000077597:Vildagliptin
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D009570:Nitriles; D011687:Purines; D011759:Pyrrolidines; D011799:Quinazolines; D000069476:Linagliptin; D000077597:Vildagliptin; D000218:Adamantane